Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Kim C, Liu SV, Subramaniam DS, Torres T, Loda M, Esposito G, et al. Phase I study of the Lu-DOTA-Tyr-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. J Immunother Cancer. 2020;8(2).

Fragliasso V, Verma A, Manzotti G, Tameni A, Bareja R, Heavican TB, et al. The novel lncRNA BlackMamba controls the neoplastic phenotype of ALK anaplastic large cell lymphoma by regulating the DNA helicase HELLS. Leukemia. 2020;34(11):2964-2980.

Fankhauser CD, Penney KL, Gonzalez-Feliciano AG, Clarke NW, Hermanns T, Stopsack KH, et al. Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. Eur Urol. 2020;78(4):637-639.

Nanayakkara J, Tyryshkin K, Yang X, Wong JJ, Vanderbeck K, Ginter PS, et al. Characterizing and classifying neuroendocrine neoplasms through microRNA sequencing and data mining. NAR Cancer. 2020;2(3):zcaa009.

Hoda SA, Hoda RS. Diagnostic Histopathology of Tumors. Am J Clin Pathol. 2020.

Zhou X, He C, Ren J, Dai C, Stevens SR, Wang Q, et al. Mature myelin maintenance requires Qki to coactivate PPARβ-RXRα-mediated lipid metabolism. J Clin Invest. 2020;130(5):2220-2236.

Magro CM, J Mulvey J, Laurence J, Seshan S, A Crowson N, Dannenberg AJ, et al. Docked severe acute respiratory syndrome coronavirus 2 proteins within the cutaneous and subcutaneous microvasculature and their role in the pathogenesis of severe coronavirus disease 2019. Hum Pathol. 2020;106:106-116.

Lee C, Huang X, Di Liberto M, Martin P, Chen-Kiang S. Targeting CDK4/6 in mantle cell lymphoma. Ann Lymphoma. 2020;4.

Magro C, Schwartz Z, Saab J, Hedayat A. Enhanced cutaneous Rock2 expression as a marker of Rho Kinase pathway activation in autoimmune disease and Kohlemeier-Degos disease. Ann Diagn Pathol. 2020;44:151414.

Dalton T, Doubrovina E, Pankov D, Reynolds R, Scholze H, Selvakumar A, et al. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Blood. 2020;135(21):1870-1881.